Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic (Timolol) ophthalmic solutions in normal tension glaucoma patients.
* Normal tension glaucoma (NTG) is the major type of glaucoma in Korea. (over 90% of glaucoma type) * Brimonidine (selective alpha 2 adrenergic agonist): neuroprotection effect by suppression of aqueous humor production and increasement of uveoscleral outflow * Timolol (non selective beta blocker): suppression effect of aqueous humor production * Combigan (fixed combination of brimonidine \& timolol): more lowering effect of intraocular pressure and enhancing the compliance of glaucoma patients
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
22
Twice per day, 1 drop at each time
Twice per day, 1 drop at each time
Seoul National University Hospital
Seoul, South Korea
RECRUITINGChange from baseline in intraocular pressure at 12 weeks
Intraocular pressure (IOP) check by Goldmann applanation tonometry with topical anesthetic eyedrop
Time frame: 12 weeks after the initial treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.